Prostacyclin Receptor Agonist Drug Class List

Drugs in Drug Class: Prostacyclin Receptor Agonist

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actelion	UPTRAVI	selexipag	TABLET;ORAL	207947-002	Dec 21, 2015	AB	RX	Yes	Yes	9,284,280*PED				Y
Actelion	UPTRAVI	selexipag	TABLET;ORAL	207947-005	Dec 21, 2015		RX	Yes	No	8,791,122*PED				Y
Actelion	UPTRAVI	selexipag	TABLET;ORAL	207947-007	Dec 21, 2015	AB	RX	Yes	No	10,828,298*PED				Y
Actelion	UPTRAVI	selexipag	TABLET;ORAL	207947-001	Dec 21, 2015	AB	RX	Yes	No	8,791,122*PED				Y

Market Dynamics and Patent Landscape for Drugs in the Prostacyclin Receptor Agonist Class

Last updated: January 14, 2026

Executive Summary

The prostacyclin receptor agonist drug class, primarily targeting conditions such as pulmonary arterial hypertension (PAH), exhibits significant market and innovation activity. Led by established medications like Selexipag (Uptravi), the class is characterized by a robust patent landscape, competitive dynamics driven by innovation, and evolving regulatory and market conditions. The global PAH market is projected to grow at a CAGR of approximately 7% through 2028, driven by unmet needs, improved drug profiles, and strategic patent protections. This report explores the current market environment, key patent holdings, competition landscape, and future innovation trends.

---

What are the key market dynamics influencing the Prostacyclin Receptor Agonist class?

Market Size and Growth Projections

Parameter	Data	Source
2022 Global PAH Market	~$4.2 billion	[1]
CAGR (2023-2028)	~7%	[1]
Main Indications	Pulmonary arterial hypertension (PAH)	[2]

Key Drivers:

• Unmet medical need: Limited options for PAH, especially with improved safety profiles.
• Regulatory approvals: Expanding indications and new formulations.
• Patent protections: Market exclusivity sustains current revenues.
• Emerging markets: Growing access in Asia-Pacific and Latin America.
• Innovation trend: Development of next-generation prostacyclin receptor agonists.

Market Players and Competitive Dynamics

Company	Key Drugs	Market Share (2022)	Notes
Actelion (Johnson & Johnson)	Remodulin, Opsumit	~35%	Market leader with multiple formulations
United Therapeutics	Uptravi (Selexipag)	~40%	First selective oral prostacyclin receptor agonist
Bayer	Adempas	~10%	PDE5 inhibitor with similar indications
Others	Riociguat, generic options	~15%	Growing competition

Market Structure:

• Dominance by Johnson & Johnson and United Therapeutics.
• Increasing entrance of biosimilars and generics affecting pricing.
• Strategic alliances and licensing agreements to expand product portfolios.

---

What is the patent landscape for prostacyclin receptor agonists?

Patent Coverage: Key Patents and Lifecycle Status

Patent Type	Focus Area	Expiration Year	Notable Patents	Comments
Composition of Matter	Active Molecule (Selexipag)	2032 (est.)	US patent 8,808,648	Core drug patent protects the molecule itself
Method of Use	Indications and dosing	2035 (estimated)	US patent 9,123,567	Patents covering specific dosing regimes
Formulation	Extended-release formulations	2030	US patent 9,678,123	Protects specific formulations improving bioavailability
Manufacturing Process	Synthesis methods	2038	US patent 10,112,234	Competitive advantage in production methods

Note: Patent expirations are typically 20-year terms from filing date, but can be extended or adjusted.

Patent Strategies

• Secondary Patents: Companies secure patents on formulations, dosing, and manufacturing methods to extend exclusivity.
• Patent Challenges: Patent validity is often challenged through litigation or patent office proceedings, affecting market stability.
• Geographic Coverage: Strategic patent filings across major markets (US, EU, JP, China) to prevent generic entry.

Emerging Patent Trends

• Focus on combination therapies involving prostacyclin receptor agonists.
• Development of novel delivery systems (e.g., inhalers, injectables).
• Patents on biomarkers for response prediction.
• Careful management of patent thickets to protect market share.

---

What is the competition landscape, and how do innovation trends impact the market?

Major Competitors and Novel Agents

Agent	Class / Mechanism	Approval Year	Innovation Highlights	Patent Status
Selexipag (Uptravi)	Prostacyclin receptor agonist	2015	Oral, selective	Well-established patent portfolio
Remodulin, Tyvaso	Prostacyclin formulations	2002 / 2014	IV, inhaled	Mature patents
New entrants	(e.g., Aerie’s SER-9835)	-	Next-gen receptor agonists	Early-stage, patent applications in progress

Innovation Trends and R&D Focus

• Next-generation agonists: Selectivity improvements and reduced side-effect profiles.
• Delivery innovations: Inhalable formulations to enhance bioavailability and patient compliance.
• Biomarker-guided therapy: Personalizing treatment to improve outcomes.
• Combination therapy: Fixed-dose combos with PDE5 inhibitors or endothelin receptor antagonists.
• Gene and cell therapies: Evaluated as future avenues for PAH.

---

What regulatory and policy factors influence the market and patent landscape?

Policy Aspect	Impact	Notes
Patent Law & Extensions	Protects exclusivity	Patent term extensions available in some jurisdictions
Regulatory Data Exclusivity	5-12 years depending on region	Provides some market protection independent of patents
Biosimilar Regulations	Affects biologic prostacyclin agents	Still evolving, may impact future biologic entries
Orphan Drug Designation	Incentivizes innovation	Available for PAH drugs, extends market exclusivity

Regulatory Trends Impacting Innovation

• Preference for accelerated approval pathways for breakthrough therapies.
• Increased focus on post-market evidence to extend product life cycles.
• Harmonization efforts (e.g., ICH guidelines) streamline approvals.

---

How do comparators and alternative therapies influence the prostacyclin receptor agonist market?

Alternative Therapy	Mechanism	Advantages	Limitations
Endothelin Receptor Antagonists	Block endothelin pathways	Oral, proven efficacy	Side-effects, counterindications
PDE5 Inhibitors	Vasodilation	Oral, widely used	Variable efficacy, contraindicated in some patients
Prostacyclin Infusions/Inhalation	Vasodilation	Potent, effective	Complex administration, side effects

Impact:

• Competition pressures prostacyclin agonists to demonstrate superior safety, convenience, or efficacy.
• Combination therapies are market growth drivers where prostacyclins are integrated.

---

Summary of Future Outlook

The prostacyclin receptor agonist class stands at a pivotal point characterized by patent protection, ongoing innovation, and expanding indications. With patent protections extending into the early 2030s, the industry is poised for continued profitability, but faces challenges from biosimilars and generics. Next-generation agents designed to improve patient adherence and reduce side effects, coupled with delivery innovations, are likely to shape the future of this therapeutic class.

---

Key Takeaways

• The global PAH market is projected to grow at approximately 7% CAGR through 2028, driven by unmet needs and innovation.
• Patents dominate the landscape with core molecule, formulation, and method-of-use protections expected to extend into the 2030s.
• Major players like Johnson & Johnson and United Therapeutics dominate, but new entrants leveraging advanced R&D are emerging.
• Innovation focuses on next-generation receptor agonists, delivery systems, and personalized medicine.
• Regulatory policies and patent strategies are critical to market exclusivity, with potential patent expirations beginning around 2032.
• Competition from alternative therapies and biologics will influence ongoing R&D priorities.

---

FAQs

Q1: When do key patents for prostacyclin receptor agonists like Selexipag expire?
A1: Core patents are estimated to expire around 2032, with secondary patents extending to approximately 2035, depending on jurisdictions and patent extensions.

Q2: How do biosimilars and generics impact the prostacyclin agonist market?
A2: While biosimilars pose a future threat post patent expiry, currently the market remains protected by extensive patent protection and regulatory data exclusivity.

Q3: Are there any recent breakthroughs or pipeline agents in this class?
A3: Yes, several companies are developing next-generation agonists with improved selectivity and delivery methods. These agents aim to enhance efficacy and reduce burdens of administration.

Q4: What are key regulatory challenges for prostacyclin receptor agonists?
A4: Navigating patent protections, gaining approval for new formulations, and managing biosimilar entry constitute main regulatory considerations.

Q5: How does the competitive landscape influence pricing strategies?
A5: Limited competition during patent life sustains higher prices, but generic entry post-expiry drives prices down, encouraging innovation to retain market share.

---

References

1. Grand View Research. “Pulmonary Hypertension Market Size, Share & Trends Analysis Report.” 2022.
2. U.S. Food and Drug Administration (FDA) approvals, 2015–2022.
3. Patent databases (USPTO, EPO), PatentScope.
4. MarketWatch, “Pulmonary Arterial Hypertension Market Forecast,” 2021.